Ob
No verificado

Obsidian Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud
12/11/2026
Web y redes sociales
Telefonía
Mercado de valores
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
1.00
06/11/2026
Industria
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
1.00
02/10/2026
Ciencia
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Salud
Oncología
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
1.00
03/08/2026
Mercado laboral
Mercado de valores
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
1.00
21/05/2026
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
1.00
21/04/2026
Eventos
Finanzas
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
1.00
14/04/2026
Mercado de valores
Mercado laboral
Biotecnología
Farmacéutica
Salud
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
1.00
12/01/2026
Mercado laboral
Biotecnología
Farmacéutica
Salud
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0